Avacta Group Share Chat (AVCT)

That is really interesting, thank you for sharing.

Https://www.fiercebiotech.com/biotech/how-novartis-readout-causing-trouble-eli-lillys-14b-radiotherapy-buy

Watching

That message would be great but doesn’t seem to match with what Al has told estura to expect next week

Whoops I’m on a boat. The sea is bloooming rough. Can just about see lol

Well said Don.

Without side effects would be even better

DTW

One line across all forms a media

“We can cure cancer without side affects “

Should sort the SP. Gla x

Great post Jersey and agree with what you say.

I would however suggest that it is now coming the time when AS and the BOD have to acknowledge the patience and support of the LTH's by addressing the SP.

Researched LTH's understand that the AVA6k trial has taken years, not because the Co is inefficient, or missing deadlines, but because the trial has been so successful we are into C7 without an MTD found

We accept that many of us are underwater because of the shambles surrounding the LFT and the promise of supplying the sovereign test. Most of us can accept that the Co were caught up in the mismanagement (and perhaps corruption) surrounding government policy, but in the end the SP went to £2.75 and we never saw an approved test

The Co has spent £10's of millions on Launch and the DX division which has had zero impact on the SP. The Science Day was great and very reassuring but the guest speakers made only passing reference to AVCT and the AVA6k trial and again, it had no impact on the SP. Likewise the recent business update, very reassuring, a commitment to not boosting, all fully supported by the researched LTH's but no impact on the SP.

Next week however is billed as a shareholder update. We have been told that we are now entering the 'commercial phase' and assuming the results are as we expect and fully QC'd, I for one am expecting to hear plans on how they are going to address the SP which continues to languish at prices similar to where it was when the trial began.

We've waited long enough and now I feel is time for the Co to reward our patience and tell us what they are planning to do to commercialise their work and hence boost the SP, no woolly generalisations, some clear plans would be great.

Https://www.google.co.uk/search?q=weight+watchers+new+york+office&ie=UTF-8&oe=UTF-8&hl=en-gb&client=safari#trex=m_t:lcl_akp,rc_f:rln,rc_ludocids:15912543193626774820,ru_gwp:0%252C7,ru_lqi:Ch93ZWlnaHQgd2F0Y2hlcnMgbmV3IHlvcmsgb2ZmaWNlIgOIAQFIoOzNz5i6gIAIWjkQABABEAQYABgBGAIYAxgEIh93ZWlnaHQgd2F0Y2hlcnMgbmV3IHlvcmsgb2ZmaWNlKgYIAhAAEAGSARBjb3Jwb3JhdGVfb2ZmaWNlqgFtEAEqIyIfd2VpZ2h0IHdhdGNoZXJzIG5ldyB5b3JrIG9mZmljZSgAMh8QASIb2iAlitqf0GdwHOFSHet21rZLoBInDKfBx71wMiMQAiIfd2VpZ2h0IHdhdGNoZXJzIG5ldyB5b3JrIG9mZmljZQ,trex_id:Vi6VFc&lpg=cid:CgIgAQ%3D%3D

Size buyers? Maybe we’ve got this all wrong. He might be referring to lots of the small buys that have gone through after he recommended the share in his local weight watchers group and their chubby buddies in New York. He might actually have been right all along.

Couldn’t agree more with that post JC and it is clear many others feel exactly the same.

Be professional in every way. Under promise and over deliver - not the other way round.

In the meantime we do the hardest thing of all. Sit on our hands.

They know you're looking so they are hiding. Until later....

Not yet, I don't know how he knows what he knows! Amazing!

Is anything happening yet Tim?

👀

Good.

Watch out for size buy orders.

I watched the open Hurstbot.

Touk - having just read your post I think it's important to reflect on the response over all rather than pick put one sentence. What we have here in AS is a responsible CEO who is articulating the need to be extremely careful in what is communicated - driven by his scientific background no doubt and the requirement for evidential based results which will face scrutiny by peers and the regulatory bodies. All of this whilst attempting to get the news out in the most effective and impactful manner. Cross the line and the company risks severe reputational damage which could not only be damaging to the company but also the light in which the results will be received. It's a tight rope walk and the fact that he is acknowledging it in a way that he knows will be made public actually gives me great comfort in the way that this is being managed by him and his team.

Sounds like you've got a bad case of FUD Derek. Best thing you can do for that is to sell as soon as the market opens. Your negative bleating won't be missed.

Yeah. Standard of care - changing over night - when approved

Estura

Thanks for info. I’m afraid that I don’t find “We’re also mindful of not raising false hopes of a quick fix for cancer patients” particularly comforting for a treatment that is going to become the defacto treatment overnight.

"I don't know why you bother seeing as you're all that confident."

Why do YOU bother though Eggy? That's what you should be asking yourself. Try a little introspection. 3 years of trolling a share that you're not even invested in. That's pretty sad behaviour I'm sure you'd agree (if you were a rational person of course).

Are you still driven to do this by your weird grudge against Myles? Or do you just like winding people up because you're embittered about your own failure in life and you see this as your revenge on people more successful/fortunate than you? Or maybe this is your only opportunity for social interaction, but you just can't resist that nasty little troll voice in your head. You know, the same one that makes you abuse nurses .

Perhaps you could let us know in the form of one of your creepy haikus.

And here we are at £1.35, thick as mince comes to mind.

So Point or Ely Lilly only have an exclusive licence for the first Canseek drug it develops.

Then any others are non-exclusive.

This opens the door for others like Novartis & Sofie to licence Radioligand Pre/Cision drugs.

Great deal by the Avacta board.

The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.

Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT.

…are lining up

I have recently suggested that people read the Sept 19th RNS and tell me that they don’t think they are on to something.

How can you read that and not think - “hang on…”

I cannot wait until 13 th - standard of care - changing over night